ELMWOOD PARK, N.J., Feb. 12, 2015 (GLOBE NEWSWIRE) -- BioReference Laboratories, Inc. (Nasdaq:BRLI) announced today the formation of a new business group — the Commercial Collaborations and Innovations ("CCI") Group. This new business group will be under the direction of newly appointed Senior Vice President, Joseph F. Donahue, and will focus on providing solutions that help accelerate pharmaceutical innovation, development and go to market activities.
Mr. Donahue was the Senior Vice President, Global Head, Business Development & Innovation at Thomson Reuters Intellectual Property & Science before joining BioReference. For the majority of the last thirty years, Mr. Donahue has spent his career supporting Life Sciences organizations with informatics solutions that have helped accelerate R&D knowledge discovery. He joins BRLI after a successful career at Thomson Reuters where he spearheaded efforts to build a global life sciences business providing competitive intelligence, intellectual property, drug pipeline, clinical trials and systems biology / big data information solutions, technology, and consulting services to life sciences companies, academia / non-profit, and government accounts.
Marc D. Grodman, MD, CEO of BRLI, commented: "BioReference has distinctive assets in the area of clinical medicine. For many years, we have characterized ourselves as an information company through our ability to correlate next generation sequencing data in oncology and rare disorders through the leading expertise of our GeneDx and GenPath business units. The extensive knowledge we have accumulated and optimized sets us apart in the industry. Mr. Donahue is a proven business and technology leader with an outstanding track record of delivering high value and impactful solutions to life sciences organizations globally, and we are delighted to have him join the team."
Joseph F. Donahue, Senior Vice President, Commercial Collaborations and Innovations, BRLI, added: "I am excited to be joining an innovative organization that is focused on improving patients' lives. The data and expertise we have accumulated, when combined with Big Data analytics, can be a game changer in this industry. I am looking forward to continuing to expand the organization that will work closely with our collaborators to convert this information into actionable insights."
The new CCI Group will be based at the BioReference Headquarters in New Jersey, USA and will work with organizations worldwide.
About BioReference Laboratories, Inc .
BioReference Laboratories is one of the largest and fastest growing full service diagnostic laboratories in the world, providing clinical testing services to physician offices, clinics, hospitals, long term care facilities and employers while also advancing drug discovery and development with disease foundations, academic and pharmaceutical partners. Our comprehensive testing capabilities and expertise spans molecular diagnostics, anatomical pathology, women's health, oncology and rare disease genetics. BioReference, and our subsidiaries, have an international presence in more than 50 countries.
Statements included in this release that are not historical in nature, are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will" or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of Bio-Reference Laboratories, Inc. and its subsidiaries. Statements looking forward in time are included in this release pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, the risks and uncertainties detailed from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or review any forward-looking information, whether as a result of new information, future developments or otherwise.
CONTACT: Tara Mackay Investor Relations Coordinator +1-201-791-2600 +1-201-791-1941 (fax) [email protected]